GPS News  
CLONE AGE
Second stem cell trial approved by FDA

disclaimer: image is for illustration purposes only
by Staff Writers
Washington (UPI) Nov 22, 2010
The second clinical trial using human embryonic stem cells has been approved by the U.S. Food and Drug Administration, the company conducting the trial said.

Biotech company Advanced Cell Technology of Marlborough, Mass., said Monday it has received approval for testing retinal cells in patients with Stargardt's macular dystrophy, a rare disease that causes progressive vision loss in children, AAAS ScienceMag.org reported.

The company says it plans to treat 12 patients with advanced cases of the disease with up to 200,000 retinal pigment epithelium cells derived from human embryo stem cells transplanted directly into the eye, Robert Lanza, ACT's chief scientific officer, says.

ACT, which applied for permission for its trial a year ago, is the second company to receive FDA approval for a human embryo stem cell trial.

In October, Geron Corp. and the University of California, Irvine, began the first clinical trial involving embryo stem cells to treat spinal cord injury patients.



Share This Article With Planet Earth
del.icio.usdel.icio.us DiggDigg RedditReddit
YahooMyWebYahooMyWeb GoogleGoogle FacebookFacebook



Related Links
The Clone Age - Cloning, Stem Cells, Space Medicine



Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News


CLONE AGE
Tests Show Bright Future For Gadonanotubes In Stem Cell Tracking
Houston TX (SPX) Nov 15, 2010
Gadonanotubes (GNTs) developed at Rice University are beginning to show positive results in a study funded by a federal stimulus grant through the National Institutes of Health (NIH) last year. The study has determined GNTs are effective in helping doctors track stems cells through the body by making them 40 times better than standard contrast agents used in magnetic resonance imaging. Con ... read more







CLONE AGE
Gene Find Could Lead To Healthier Food And Better Biofuel

New Disease-Resistant Food Crops In Prospect

More Efficient Use Of Farm Inputs Key To Growth

China milk campaigner 'forced to sack lawyers': rights group

CLONE AGE
Chaogates Hold Promise For The Semiconductor Industry

Caltech Physicists Demonstrate A Four-Fold Quantum Memory

Building A Racetrack Memory

Microsoft sues Motorola over 'excessive' royalty demands

CLONE AGE
'Very rare' oxygen bottle blast holed Qantas jet: probe

India approves new airport for Mumbai

Airbus CEO takes dive as A380 has issues

Air China announces 4.49 billion-dollar Airbus deal

CLONE AGE
World Debut Of Honda Fit EV Concept Electric Vehicle

Daewoo, Doosan in Indonesian vehicle deal

China's SAIC buys 500-million-dollar stake in General Motors

Toyota unveils hybrid car push

CLONE AGE
China, Botswana sign economic deals

Peru, Yale reach agreement on artifacts

Commodity prices drop on eurozone, China fears

Exhibit threads Chinese, Roman empires with silk

CLONE AGE
Cameroon Timber Tax Shows Problems Distributing REDD Payments To Locals

Macedonia plants seven million trees to revive its forests

'Forgotten' forests store carbon

Tropical Forest Diversity Increased During Ancient Global Warming Event

CLONE AGE
Climate Change On The Go

Art on planetary scale shines spotlight on climate change

Google agrees to delete Street View data in Britain

Eruption At Mount Merapi

CLONE AGE
EMPA Identifies Reaction Pathway To Fabricate Graphene-Like Materials

Strength Of Graphene Lies In Its Defects

Novel Ocean-Crust Mechanism Could Affect Global Carbon Budget

Carbon price needed to end costly uncertainty: Australia PM


The content herein, unless otherwise known to be public domain, are Copyright 1995-2010 - SpaceDaily. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by SpaceDaily on any Web page published or hosted by SpaceDaily. Privacy Statement